Prof. Dr. Martin Smiesko
Lecturer
Research associate
Lecturer
Martin Smiesko
Philosophisch-Naturwissenschaftliche Fakultät
Departement Pharmazeutische Wissenschaften
Departementsleitung

Lecturer

Klingelbergstrasse 50
4056 Basel
Schweiz

Tel. +41 61 207 15 63
martin.smiesko@unibas.ch


Philosophisch-Naturwissenschaftliche Fakultät
Departement Pharmazeutische Wissenschaften
Computational Pharmacy

Research associate

Klingelbergstrasse 50
4056 Basel
Schweiz

Tel. +41 61 207 15 63
martin.smiesko@unibas.ch


Philosophisch-Naturwissenschaftliche Fakultät
Departement Pharmazeutische Wissenschaften
Computational Pharmacy

Lecturer

Klingelbergstrasse 50
4056 Basel
Schweiz

Tel. +41 61 207 15 63
martin.smiesko@unibas.ch

Martin Smiesko graduated in medicinal chemistry from the Faculty of Pharmacy of Comenius University, Bratislava, Slovakia in 1999. In 2003 he obtained his PhD. at the same university in the group of Prof. Milan Remko with his thesis focusing on Molecular Modeling of ACE inhibitors. From 2003 to 2005 he worked as a post-doctoral fellow in Dr. Emilio Benfenati’s group at the Institute of Pharmacological Research "Mario Negri" in Milano, Italy, where he worked on the development of predictive models for ecotoxicology. Then he spent one year working on the development of cholic acid-based receptors for chiral separations at biotech company anterio consult & research in Mannheim, Germany. In September 2006 Martin joined the group of Prof. Angelo Vedani at the group of Molecular Modeling at the University of Basel as a research associate. After completing his Habilitation in April 2014 he was promoted to "Privatdozent" (Senior Lecturer) in the field of Computer-Aided Drug Discovery and Toxicology and in September 2022 he was promoted to “Titularprofessor”. His main area of interest is development and application of  structure-based methods for drug design and predictive toxicology. He is the co-author of more than 100 publications in leading scientific journals, numerous posters and several international patents, and the main developer of the off-target screening platforms VirtualToxLab and PanScreen.